Damian Bell obtained his PhD in Annette Dolphin’s lab, University College London. His post-doctoral research in Steve Siegelbaum’s lab, Columbia University, Nev York City, focused onHCN ion channel voltage-sensing. On returning to the United Kingdom, he worked on the burgeoning automated patch clamp platforms, specializing in ion channel drug discovery forlarge (AstraZeneca, GSK) and small pharma (Convergence); CROs (Charles River Laboratories, formerly BioFocus; Metrion); & the antibody engineering biotech IONTAS. Damian joined Sophion Bioscience in October, 2020, a Danish technology Research&Development company & global leaders in automated patch clamp.
See more on LinkedIn: www.linkedin.com/in/Damian-Bell